Search

Displaying results 2551 - 2560 of 5898 in total
  1. Drug

    Mepolizumab

    go.drugbank.com/drugs/DB06612
    ApprovedInvestigational

    This indication was subsequently expanded to cover EGPA on December 12, 2017, and HES on September 25, 2020.[L16518] … Activated eosinophils further stimulate an inflammatory response and also induce tissue lesions and promote fibrosis, all of which contribute to the multifactorial symptomatology of hypereosinophilic diseases

  2. Drug

    Fencamfamin

    go.drugbank.com/drugs/DB01463
    ApprovedIllicitWithdrawn

    It is especially useful in patients with chronic conditions due to its favourable safety profile. … It is around half the potency of [dexamphetamine], and is prescribed at a dose of 10-60mg, although abusers of the drug tend to rapidly develop tolerance and escalate their dose.

  3. Drug

    Benzthiazide

    go.drugbank.com/drugs/DB00562
    Approved

    Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity. … Benzthiazide is used to treat hypertension and edema. Like other thiazides, benzthiazide promotes water loss from the body (diuretics).

  4. Drug

    Streptozocin

    go.drugbank.com/drugs/DB00428
    ApprovedInvestigational

    It is used as an antineoplastic agent and to induce diabetes in experimental animals.

  5. Drug

    Sulfamethazine

    go.drugbank.com/drugs/DB01582
    ApprovedVet approvedWithdrawn

    It has a spectrum of antimicrobial action similar to other sulfonamides.

  6. Drug

    Etoperidone

    go.drugbank.com/drugs/DB09194
    ApprovedWithdrawn

    Etoperidone is an atypical antidepressant introduced in Europe in 1977. It is a phenylpiperazine-substituted triazole derivative with a composition that classifies it as an analog of tradozone and presents a similar pharmacological profi...

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  7. Drug

    Gastric intrinsic factor

    go.drugbank.com/drugs/DB09349
    Approved

    is currently in the marketed (but unapproved) product Hematogen in combination with cyanocobalamin (synthetic Vitamin B12), ferrous fumarate, and ascorbic acid for the treatment of anemias responsive to

  8. Drug

    Galcanezumab

    go.drugbank.com/drugs/DB14042
    ApprovedInvestigational

    [A33105] Although several small-molecule CGRP receptor antagonists have been developed, humanized monoclonal antibodies like galcanezumab are specifically designed to selectively bind to CGRP entities … A pregnancy exposure registry has been established to evaluate the safety of this drug in pregnant women.[L42060]

  9. Drug

    Tildrakizumab

    go.drugbank.com/drugs/DB14004
    ApprovedInvestigational

    The Food and Drug Administration (FDA) approved ILUMYA (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy

  10. Drug

    KP-1461

    go.drugbank.com/drugs/DB05644
    Investigational

    KP-1461 is a potent, non-chain-terminating, mutagenic deoxyribonucleoside analogue. Designated a DNA covert nucleoside, the drug consists of a modified base that incorporates randomly into HIV and pairs with multiple bases.